Name: 5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference
Start: 2024-03-07
End: 2024-03-08
Location: Park Plaza Victoria London by Radisson, 239 Vauxhall Bridge Rd, Pimlico, London SW1V 1EQ, UK

EVENT OVERVIEW

Leveraging next gen technologies beyond conventional biomarker drug discovery

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

20+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Challenges in NGS based CDx and the Importance of imaging biomarkers for precision medicine.

Opportunity to develop long-lasting business relationships and networking opportunities with senior peers. Get the Opportunity to get your queries handled by Biomarker experts in one on one session.

Facilitated networking sessions to ensure quality interactions along with Case studies from experts who have successfully created and developed a biomarker

The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th - 8th March 2024 in London, UK would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.

This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.

Clinical biomarker identification and qualification
Biomarkers and personalized medicine
Assay development and validation
NGS and novel technologies in biomarker discovery
Commercialization of biomarkers in therapeutic and CDx applications

Researchers, scientists, clinicians, academicians and professionals From Pharmaceutical companies, Bio-pharma companies, Universities and Research Institutes.

Departments:

Biomarker discovery/development | Translational research | Clinical Biomarker | Biomarkers in IO and Neurological disorders

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION
Keynote Presentation - ICT01, an anti-BTN3A mAb activating Vg9Vd2 cells Emmanuel Valentin, Vice President, Translational Medicine, Imcheck Therapeutics	09:00 - 09:30
Biomarker assay development and validation for cancer treatment Nathalie Steinhoff, Scientist, Cancer Immunotherapy, Numab Therapeutics AG Valerie Balme, Associate Director, Business Development, Veracyte	09:30 - 10:00
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Transforming Oncology with Predicine’s Liquid Biopsy Solutions Dr. Pan Du, Co-founder, president and CTO , Predicine	11:15 - 11:45
Combination Strategies for Personalised Cancer Therapy Sreejith Raveendran, Assistant Professor, Teesside University	11:45 - 12:15
Sample quality strategies, operations and patient centricity for biomarker analysis Debora Souza Da Costa, Senior Biosample Project Leader., Roche	12:15 - 12:45
Comprehensive Biomarker Strategies To Decipher The Tumor Microenvironment: From Tissue To High-Quality Spatial Insights Angela Vasaturo , Director of Scientific Affairs, Ultivue	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
ROLE OF BIOMARKERS IN PERSONALIZED MEDICINE
AI-driven analysis of morphological biomarkers for trials in haemato-oncology Daniel Royston, Consultant Clinical Advisor, Ground Truth Labs	14:15 - 14:45
AI in medicine - A paradigm shift for the diagnostic industry Thomas Gohl, Market Development Manager, Roche Diagnostics	14:45 - 15:15
Development of a colorectal cancer methylation panel and an actionable cancer mutation panel using targeted bisulfite next-generation sequencing Collin Hudzik, Scientist, EpigenDx	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Lifestyle and epigenetic changes Aparna Duggirala, Lecturer, Clinical Genetics, University of Derby	16:30 - 17:00
Back translation of preclinical models to humans Maria Dermit, Computational Biologist, Novo Nordisk	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 18:00
Drinks Reception & Networking ....End of Day 1....	18:00 - 18:00

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
FROM BIOMARKERS TO CDx: STRATEGIES TO ACCELERATE CDx DEVELOPMENT AND COMMERCIALIZATION
Keynote Presentation : Use of biomarkers in clinical development to guide dosing regimen recommendation with the use of modelling and simulations models. Patrick Brossard, Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB	09:00 - 09:30
Tracking challenging pharmacodynamic biomarkers in normal tissue on Phase I clinical trials of new oncology agents Karen Swales, Senior Scientific Officer, Clinical PD Biomarker Group, The Institute of Cancer Research	09:30 - 10:00
With only 1/500 Biomarkers reaching the patient what can we do better? Christopher Peters, Clinical Senior Lecturer, Imperial College London	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
CLINICAL APPLICATIONS OF BIOMARKERS IN IMMUNOLOGY, NEUROLOGY, AND OTHER DISEASES
Anti-CD89 antibody for personalized treatment of IgA-mediated inflammatory disorders: Autoantigen-specific IgA, a biomarker with strong effector functions. Louis Boon, CSO and Board Member, JJP Biologics	11:15 - 11:45
The Lymphocyte Stability Index - a pan-cancer biomarker for response to immune checkpoint blockade Robert Watson, Clinical Lecturer, University of Oxford	11:45 - 12:15
Histone based liquid biopsies for the screening of cancer and cardiovascular diseases Manlio Vinciguerra, European Research Area (ERA) Chair, Medical University Varna & Faculty, Liverpool John Moores University, Liverpool	12:15 - 12:45
Generating pseudo-time progression of mucosal inflammation during Inflammatory Bowel Disease using spatially resolved multi-omics data Priyank Patel, Senior Scientist, Department of Immunology & Respiratory Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Panel Discussion: What are the biggest challenges faced in developing an assay: why and what have we learnt from it ? Patrick Brossard, Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB Christopher Peters, Clinical Senior Lecturer, Imperial College London Maria Dermit, Computational Biologist, Novo Nordisk Manlio Vinciguerra, European Research Area (ERA) Chair, Medical University Varna & Faculty, Liverpool John Moores University, Liverpool Fernando Oneissi Martinez Estrada, Senior Lecturer in Innate Immunology, University of Surrey	14:15 - 14:45
Closing Remarks from the Chairperson	14:45 - 14:50
END OF CONFERENCE	14:50 - 14:50